Pasithea Capex To Revenue vs Total Revenue Analysis

KTTAW Stock

USD 0.02 0 11.11%

Pasithea Therapeutics financial indicator trend analysis is much more than just breaking down Pasithea Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pasithea Therapeutics is a good investment. Please check the relationship between Pasithea Therapeutics Capex To Revenue and its Total Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Capex To Revenue vs Total Revenue

Capex To Revenue vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pasithea Therapeutics Capex To Revenue account and Total Revenue. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Pasithea Therapeutics' Capex To Revenue and Total Revenue is 0.96. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Pasithea Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Pasithea Therapeutics' Capex To Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Pasithea Therapeutics Corp are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Capex To Revenue i.e., Pasithea Therapeutics' Capex To Revenue and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Total Revenue

Total revenue comprises all receipts Pasithea Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Pasithea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Pasithea Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 31 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 16.32 in 2024.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	4.5M	15.3M	16.0M	9.9M
Depreciation And Amortization	1.4K	5.1K	648.5K	680.9K

Other Operating Expenses Depreciation And Amortization

Pasithea Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Long Term Debt Total	Current Deferred Revenue	Net Receivables	Inventory	Short Term Debt	Intangible Assets
Total Assets		0.53	0.7	1.0	-0.96	-0.63	0.68	0.98	0.98	0.94	0.86	0.95	0.91	1.0	0.99	-0.25	0.98	-0.25	-0.42	0.6	-0.42	-0.42	-0.42	-0.42	-0.41	-0.41
Other Current Liab	0.53		0.8	0.52	-0.35	-0.94	0.94	0.46	0.46	0.74	0.47	0.7	0.73	0.52	0.46	-0.95	0.43	-0.95	-0.99	0.18	-0.99	-0.99	-0.99	-0.99	-0.98	-0.88
Total Current Liabilities	0.7	0.8		0.68	-0.54	-0.94	0.92	0.57	0.57	0.9	0.8	0.89	0.93	0.68	0.58	-0.66	0.55	-0.66	-0.77	0.66	-0.76	-0.74	-0.76	-0.77	-0.79	-0.53
Total Stockholder Equity	1.0	0.52	0.68		-0.97	-0.61	0.67	0.99	0.99	0.93	0.85	0.94	0.9	1.0	0.99	-0.23	0.98	-0.23	-0.4	0.59	-0.4	-0.41	-0.4	-0.4	-0.39	-0.4
Net Debt	-0.96	-0.35	-0.54	-0.97		0.42	-0.48	-0.99	-0.99	-0.83	-0.74	-0.86	-0.8	-0.97	-0.98	0.05	-0.99	0.05	0.22	-0.48	0.22	0.22	0.22	0.22	0.22	0.2
Retained Earnings	-0.63	-0.94	-0.94	-0.61	0.42		-1.0	-0.51	-0.51	-0.85	-0.7	-0.81	-0.86	-0.61	-0.52	0.85	-0.48	0.85	0.92	-0.51	0.92	0.91	0.92	0.92	0.92	0.79
Accounts Payable	0.68	0.94	0.92	0.67	-0.48	-1.0		0.58	0.58	0.88	0.73	0.84	0.88	0.67	0.58	-0.83	0.55	-0.83	-0.91	0.5	-0.91	-0.91	-0.91	-0.91	-0.9	-0.81
Cash	0.98	0.46	0.57	0.99	-0.99	-0.51	0.58		1.0	0.87	0.77	0.89	0.83	0.99	1.0	-0.16	1.0	-0.16	-0.33	0.48	-0.33	-0.34	-0.33	-0.33	-0.31	-0.36
Cash And Short Term Investments	0.98	0.46	0.57	0.99	-0.99	-0.51	0.58	1.0		0.87	0.77	0.89	0.83	0.99	1.0	-0.16	1.0	-0.16	-0.33	0.48	-0.33	-0.34	-0.33	-0.33	-0.31	-0.36
Common Stock Shares Outstanding	0.94	0.74	0.9	0.93	-0.83	-0.85	0.88	0.87	0.87		0.9	1.0	0.99	0.93	0.88	-0.5	0.86	-0.5	-0.65	0.66	-0.65	-0.65	-0.65	-0.65	-0.65	-0.56
Other Current Assets	0.86	0.47	0.8	0.85	-0.74	-0.7	0.73	0.77	0.77	0.9		0.89	0.9	0.85	0.78	-0.22	0.76	-0.22	-0.38	0.91	-0.38	-0.39	-0.38	-0.38	-0.37	-0.37
Other Stockholder Equity	0.95	0.7	0.89	0.94	-0.86	-0.81	0.84	0.89	0.89	1.0	0.89		0.99	0.94	0.89	-0.46	0.87	-0.46	-0.61	0.65	-0.61	-0.6	-0.61	-0.61	-0.62	-0.5
Total Liab	0.91	0.73	0.93	0.9	-0.8	-0.86	0.88	0.83	0.83	0.99	0.9	0.99		0.9	0.84	-0.5	0.81	-0.5	-0.66	0.68	-0.65	-0.64	-0.65	-0.66	-0.66	-0.51
Net Invested Capital	1.0	0.52	0.68	1.0	-0.97	-0.61	0.67	0.99	0.99	0.93	0.85	0.94	0.9		0.99	-0.23	0.98	-0.23	-0.4	0.59	-0.4	-0.41	-0.4	-0.4	-0.39	-0.4
Total Current Assets	0.99	0.46	0.58	0.99	-0.98	-0.52	0.58	1.0	1.0	0.88	0.78	0.89	0.84	0.99		-0.16	1.0	-0.16	-0.33	0.49	-0.33	-0.34	-0.33	-0.33	-0.32	-0.36
Capital Stock	-0.25	-0.95	-0.66	-0.23	0.05	0.85	-0.83	-0.16	-0.16	-0.5	-0.22	-0.46	-0.5	-0.23	-0.16		-0.13	1.0	0.98	0.01	0.98	0.98	0.98	0.98	0.98	0.86
Net Working Capital	0.98	0.43	0.55	0.98	-0.99	-0.48	0.55	1.0	1.0	0.86	0.76	0.87	0.81	0.98	1.0	-0.13		-0.13	-0.3	0.47	-0.3	-0.31	-0.3	-0.3	-0.28	-0.34
Common Stock	-0.25	-0.95	-0.66	-0.23	0.05	0.85	-0.83	-0.16	-0.16	-0.5	-0.22	-0.46	-0.5	-0.23	-0.16	1.0	-0.13		0.98	0.01	0.98	0.98	0.98	0.98	0.98	0.86
Non Currrent Assets Other	-0.42	-0.99	-0.77	-0.4	0.22	0.92	-0.91	-0.33	-0.33	-0.65	-0.38	-0.61	-0.66	-0.4	-0.33	0.98	-0.3	0.98		-0.13	1.0	1.0	1.0	1.0	1.0	0.86
Property Plant And Equipment Gross	0.6	0.18	0.66	0.59	-0.48	-0.51	0.5	0.48	0.48	0.66	0.91	0.65	0.68	0.59	0.49	0.01	0.47	0.01	-0.13		-0.13	-0.13	-0.13	-0.13	-0.13	-0.11
Short Long Term Debt Total	-0.42	-0.99	-0.76	-0.4	0.22	0.92	-0.91	-0.33	-0.33	-0.65	-0.38	-0.61	-0.65	-0.4	-0.33	0.98	-0.3	0.98	1.0	-0.13		1.0	1.0	1.0	0.99	0.88
Current Deferred Revenue	-0.42	-0.99	-0.74	-0.41	0.22	0.91	-0.91	-0.34	-0.34	-0.65	-0.39	-0.6	-0.64	-0.41	-0.34	0.98	-0.31	0.98	1.0	-0.13	1.0		1.0	1.0	0.98	0.91
Net Receivables	-0.42	-0.99	-0.76	-0.4	0.22	0.92	-0.91	-0.33	-0.33	-0.65	-0.38	-0.61	-0.65	-0.4	-0.33	0.98	-0.3	0.98	1.0	-0.13	1.0	1.0		1.0	0.99	0.88
Inventory	-0.42	-0.99	-0.77	-0.4	0.22	0.92	-0.91	-0.33	-0.33	-0.65	-0.38	-0.61	-0.66	-0.4	-0.33	0.98	-0.3	0.98	1.0	-0.13	1.0	1.0	1.0		1.0	0.86
Short Term Debt	-0.41	-0.98	-0.79	-0.39	0.22	0.92	-0.9	-0.31	-0.31	-0.65	-0.37	-0.62	-0.66	-0.39	-0.32	0.98	-0.28	0.98	1.0	-0.13	0.99	0.98	0.99	1.0		0.82
Intangible Assets	-0.41	-0.88	-0.53	-0.4	0.2	0.79	-0.81	-0.36	-0.36	-0.56	-0.37	-0.5	-0.51	-0.4	-0.36	0.86	-0.34	0.86	0.86	-0.11	0.88	0.91	0.88	0.86	0.82

Click cells to compare fundamentals

Pasithea Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pasithea Capex To Revenue vs Total Revenue Analysis

Capex To Revenue vs Total Revenue

Capex To Revenue vs Total Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Total Revenue

Pasithea Therapeutics fundamental ratios Correlations

Pasithea Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Pasithea Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Net Working Capital	+ 1.0	Cash

Accounts Payable	- 1.0	Retained Earnings
Net Working Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Inventory	- 0.99	Other Current Liab
Net Receivables	- 0.99	Other Current Liab